| Active substance | Lenvatinib |
| Holder | Eisa Ltd. |
| Status | Closed |
| Indication | Lenvatinib’s indication is the treatment of radioiodine-refractory differentiated thyroid cancer. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 03/05/2018 |